A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510117-26-00

Acronym

UCDCRC/23/06

Enrollment

Registered

2024-05-31

Start date

Unknown

Completion date

2025-05-06

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Brief summary

6-month Progression-free survival (PFS) with median PFS included in statistical analysis

Detailed description

Safety, Overall survival time, Best overall response rate, EXPLORATORY ENDPOINT: Changes in immune parameters in the peripheral blood over time

Interventions

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGDoxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

DRUGNiopam 300

DRUGsolution for injection

DRUGglass bottles

DRUGOmnipaque 240 mg I/ml Solution for Injection.

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGOmnipaque 300 mg I/ml Solution for Injection.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
6-month Progression-free survival (PFS) with median PFS included in statistical analysis	—

Secondary

Measure	Time frame
Safety, Overall survival time, Best overall response rate, EXPLORATORY ENDPOINT: Changes in immune parameters in the peripheral blood over time	—

Countries

Ireland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026